CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics
Retrieved on:
Tuesday, March 1, 2022
Intellectual property, GMP, Patent, Method, Trade, CRISPR, University, Genomics, Eukaryote, Sale, Biofuel, Broad Institute, RNA vaccine, CVC, Emmanuelle, Enzyme, Synthetic biology, Patent Trial and Appeal Board, PTAB, University of California, Riverside Citrus Variety Collection, Cas9, CEO, Research, Pharmaceutical industry, Rolling (metalworking), EU
CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.
Key Points:
- CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.
- These patents cover a variety of compositions and methods for CRISPR/Cas9 gene editing, including dual-guide and single-guide formats.
- In addition to its substantial portfolio of granted CRISPR/Cas9 patents in the US, CVC maintains fundamental CRISPR/Cas9 patents in over 80 countries including the EU, China, Japan and elsewhere.
- Eric Rhodes, CEO of ERS Genomics said; "We remain convinced that the compositions, methods and techniques in the CVC portfolio of patents are the essential intellectual property for the practice of CRISPR/Cas9 gene editing."